Your browser doesn't support javascript.
loading
Foot drop in patients treated with bortezomib - a case series and review of the literature.
Vaxman, Iuliana; Mauerman, Michelle L; Gatt, Moshe L; Berger, Tamar; Gertz, Morie A.
Afiliação
  • Vaxman I; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Mauerman ML; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikvah, Israel.
  • Gatt ML; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Berger T; Division of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Gertz MA; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Leuk Lymphoma ; 63(3): 722-728, 2022 03.
Article em En | MEDLINE | ID: mdl-34702127
ABSTRACT
Bortezomib-induced peripheral neuropathy (BIPN) has a profound impact on quality of life, which is an important issue considering the growing number of survivors of multiple myeloma and amyloidosis. BIPN is typically symmetric, distal, "stocking and glove" distribution and predominantly consists of sensory rather than motor symptoms. In this case series, we report an acute neurotoxicity syndrome induced by bortezomib, which is clinically distinct from BIPN by not being peripheral and distal. We describe six patients that developed unilateral or bilateral foot drop attributed to bortezomib. With bortezomib discontinuation symptoms improved gradually over months to years.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Periférico / Neuropatias Fibulares / Mieloma Múltiplo / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Periférico / Neuropatias Fibulares / Mieloma Múltiplo / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article